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So far, progress regarding the use of both in vitro and in
vivo regenerative medicine models already offers hope
for the application of different types of stem cells as a
powerful new therapeutic option to treat different dis-
orders that were previously thought to be untreatable
[1]. Remarkable achievements in cell biology resulting
in the isolation and characterization of various stem cells
and progenitor cells has increased the expectation for
the development of a new approach to the treatment
of genetic and developmental human diseases [2].
Based on our current knowledge and strong sup-
porting evidence from previous experience, different
types of stem cell populations are capable of undergo-
ing differentiation or trans-differentiation into function-
ally active cells for use in therapeutic interventions [3].
However, some scientists have raised concerns regard-
ing the benefits of generating thyrocytes from stem cells
as a valuable potential therapeutic option [4]: It has been
stated that the availability of an effective, economical,
standardized, and well-tolerated hormone replacement
therapy for hypothyroid states may render stem cell–
based treatments unnecessary in most cases, and if such
a therapeutic option is to be used for transplantation
therapy, certain requirements should be met [4].
We believe that before reaching such a conclusion,
some important considerations should be kept in mind:
1. We admit that while there are medicines like
levothyroxine and liothyronine, which, thanks to
new technology, are manufactured with a low price,
trying to cure patients inflicted with hypothyroid-
ism using stem cells is not very reasonable and cost
effective. Yet, can we generalize this argument with
certainty and without a comprehensive evaluation
or studies regarding cost effectiveness to patients
suffering from hypothyroidism or, most important-
ly, congenial thyroid aplasia? In fact, in these spe-
cial cases, we should consider the lifelong costs of
drug therapy and different follow-up experiments
at certain intervals, and still keep in mind the costs
of probable mismanagement in childhood or preg-
nancy of these patients. Only after these calculations
can one declare with confidence that these studies
do not have practical justification at the present time.
2. In those patients suffering from congenital forms of
hypothyroidism, destruction by the recipient’s im-
mune system seems not to be an important concern,
and immunosuppression to bypass the immune sys-
tem response is not required, because using the pa-
tient’s own stem cells, the resulting thyroglobulin-
producing cells are not immunologically rejectable
by the immune system.
3. Due to the fact that currently stem cells and umbili-
cal cord banks are so strictly defined and available,
it seems that this mission is investigationally more
practical than in the past, particularly for those chil-
dren suffering from developmental aplasia of the
thyroid gland.
4. Studies performed on stem cells, targeting their con-
version into functionally mature tissue, are not nec-
essarily seeking to result in the clinical application
of the differentiated cells; In fact, still one of the im-
portant goals of these studies is to get acquainted
with the natural process of development of mature
cells from their immature progenitors during the
embryonic period onwards, which can produce
valuable results as knowledge of the developmen-
tal processes during embryogenesis [5]. For exam-
ple, the cellular and molecular mechanisms leading
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to thyrocyte developmental abnormalities are rela-
tively unknown [5]. This lack of understanding
stems from the lack of a good model system to study
thyrocyte development and differentiation [5].
Hence, the knowledge reached through these stud-
ies can prove to be a breakthrough in preventing
developmental disorders like aplasia, hypoplasia, or
ectopic thyroid. Meanwhile, many researchers con-
duct these studies to understand the molecular and
cellular basis of cancer development. Owing to the
fact that thyroid cancer is the most prevalent cancer
in the endocrine system of the body, one cannot dis-
miss these studies and consider them worthless.
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